Luteolin alleviates renal ischemia-reperfusion injury in streptozotocin induced diabetic rats by inhibiting metalloenzymes expression

1 Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. JASN. 2003;14:2199-210. Search in Google Scholar

2 Lejay A, Fang F, John R, Van JAD, Barr M, Thaveau F, et al. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. JMCC. 2016;91:11-22. Search in Google Scholar

3 Zhang Y, Hu F, Wen J, Wei X, Zeng Y, Sun Y, et al. Effects of sevoflurane on NF-кB and TNF-α expression in renal ischemia–reperfusion diabetic rats. IR. 2017;66(10):901-10. Search in Google Scholar

4 Chan KL. Role of Nitric Oxide in ischemia and reperfusion injury. Curr Med Chem Anti-Inflammatory & Anti-Allergy Agents. 2002;1;1-13. Search in Google Scholar

5 Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol. 2005;288:91-7. Search in Google Scholar

6 Gong DJ, Wang L, Yang YY, Zhang JJ, Liu XH. Diabetes aggravates renal ischemia and reperfusion injury in rats by exacerbating oxidative stress, inflammation, and apoptosis. Ren Fail. 2019;41(1): 750-61. Search in Google Scholar

7 Kunugi S, Shimizu A, Kuwahara N, Du X, Takahashi M, Terasaki Y, et al. Inhibition of matrix metalloproteinases reduces ischemiareperfusion acute kidney injury. Lab Invest. 2011;91(2):170-80. Search in Google Scholar

8 Za k iyanov O, Ka lousová M, Zima T, Tesař V. Matri x metalloproteinases in renal diseases: a critical appraisal. Kidney Blood Press Res. 2019;44:298-330. Search in Google Scholar

9 Mathalone N, Lahat N, Rahat MA, Bahar-Shany K, Oron Y, Geyer O. The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia. Graefe’s Arch Clin Exp Ophthalmol. 2007;245(5):725-32. Search in Google Scholar

10 Muhs BE, Plitas G, Delgado Y, Ianus I, Shaw JP, Adelman MA, et al. Temporal expression and activation of matrix metalloproteinases-2, -9, and membrane type 1 – Matrix metalloproteinase following acute hindlimb ischemia. J Surg Res. 2003;111(1):8-15. Search in Google Scholar

11 Roach DM, Fitridge RA, Laws PE, Millard SH, Varelias A, Cowled PA. Up-regulation of MMP-2 and MMP-9 leads to degradation of type IV collagen during skeletal muscle reperfusion injury; protection by the MMP inhibitor, doxycycline. Eur J Vasc Endovasc Surg. 2002;23(3):260-9. Search in Google Scholar

12 Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation. 2000;101(15):1833-9. Search in Google Scholar

13 Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JRB, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002;106(12):1543-9. Search in Google Scholar

14 Basile DP, Fredrich K, Weihrauch D, Hattan N, Chilian WM, Angiostatin WMC. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. J Physiol Renal Physiol. 2004;286:893-902. Search in Google Scholar

15 Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol. 2005;288:91-7. Search in Google Scholar

16 Melin J, Hellberg O, Larsson E, Zezina L, Fellström BC. Protective effect of insulin on ischemic renal injury in diabetes mellitus. Kidney Int. 2002;61(4):1383-92. Search in Google Scholar

17 Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH, Cheng S, et al. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J. 2006;20(11):1898-900. Search in Google Scholar

18 Dejonck heere E, Vandenbroucke R E, Libert C. Matri x metalloproteinases as drug targets in ischemia/reperfusion injury. Drug Discovery Today. 2011;16:762-78. Search in Google Scholar

19 Dong Y, Zhao H, Man J, Fu S, Yang L. MMP-9-mediated regulation of hypoxia-reperfusion injury-related neutrophil inflammation in an in vitro proximal tubular cell model. Ren Fail. 2021;43(1):900-10. Search in Google Scholar

20 Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, et al. Histone deacetylase-2 is a key regulator of diabetes-and transforming growth factor-1-induced renal injury. Am J Physiol Renal Physiol. 2009;297:729-39. Search in Google Scholar

21 Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, et al. Histone deacetylase inhibition reduces myocardial ischemia‐ reperfusion injury in mice. FASEB J. 2008;22(10):3549-60. Search in Google Scholar

22 Fan J, Alsarraf O, Dahrouj M, Platt KA, Chou CJ, Rice DS, et al. Inhibition of HDAC2 protects the retina from ischemic injury. Invest Ophthalmol Vis Sci. 2013;54(6):4072-80. Search in Google Scholar

23 Aufhauser DD, Hernandez P, Concors SJ, O’Brien C, Wang Z, Murken DR, et al. HDAC2 targeting stabilizes the CoREST complex in renal tubular cells and protects against renal ischemia/reperfusion injury. Sci Rep. 2021;11(1). Search in Google Scholar

24 Cosentino CC, Skrypnyk NI, Brilli LL, Chiba T, Novitskaya T, Woods C, et al. Histone deacetylase inhibitor enhances recovery after AKI. JASN. 2013;24(6):943-53. Search in Google Scholar

25 Du Y, Tang G, Yuan W. Suppression of HDAC2 by sodium butyrate alleviates apoptosis of kidney cells in db/db mice and HG-induced NRK-52E cells. Int J Mol Med. 2020;45(1):210-22. Search in Google Scholar

26 Ma X, Wang Q. short-chain fatty acids attenuate renal fibrosis and enhance autophagy of renal tubular cells in diabetic mice through the HDAC2/ULK1 axis. Endocrinol Metab. 2022;37(3):432-43. Search in Google Scholar

27 Xiong C, Wu Q, Fang M, Li H, Chen B, Chi T. Protective effects of luteolin on nephrotoxicity induced by long-term hyperglycaemia in rats. J Int Med Res. 2020;48(4). Search in Google Scholar

28 Zhang M, He L, Liu J, Zhou L. Luteolin attenuates diabetic nephropathy through suppressing inflammatory response and oxidative stress by inhibiting STAT3 pathway. Expe Clin Endocrinol Diabetes. 2021;129(10):729-39. Search in Google Scholar

29 Wang GG, Lu XH, Li W, Zhao X, Zhang C. Protective effects of luteolin on diabetic nephropathy in STZ-induced diabetic rats. Evid Based Complement Alternat Med. 2011;2011:323171. Search in Google Scholar

30 Aziz N, Kim MY, Cho JY. Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. J Ethnopharmacol. 2018;225:342-58. Search in Google Scholar

31 Lv J, Zhou D, Wang Y, Sun W, Zhang C, Xu J, et al. Effects of luteolin on treatment of psoriasis by repressing HSP90. Int Immunopharmacol. 2020;79. Search in Google Scholar

32 López-Lázaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem. 2009;9(1):31-59. Search in Google Scholar

33 Arslan BY, Arslan F, Erkalp K, Alagöl A, Sevdi MS, Yıldız G, et al. Luteolin ameliorates colistin-induced nephrotoxicity in the rat models. Ren Fail. 2016;38(10):1735-40. Search in Google Scholar

34 Domitrović R, Cvijanović O, Pugel EP, Zagorac GB, Mahmutefendić H, Škoda M. Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney. Toxicology. 2013;310:115-23. Search in Google Scholar

35 Xin S bin, Yan H, Ma J, Sun Q, Shen L. Protective effects of luteolin on lipopolysaccharide-induced acute renal injury in mice. MSM. 2016;22:5173-80. Search in Google Scholar

36 Hong X, Zhao X, Wang G, Zhang Z, Pei H, Liu Z. Luteolin treatment protects against renal ischemia-reperfusion injury in rats. Mediators Inflamm. 2017;2017. Search in Google Scholar

37 Liu Y, Shi B, Li Y, Zhang H. Protective effect of luteolin against renal ischemia/reperfusion injury via modulation of pro-inflammatory cytokines, oxidative stress and apoptosis for possible benefit in kidney transplant. MSM. 2017;23:5720-7. Search in Google Scholar

38 Bonino B, Leoncini G, De Cosmo S, Greco E, Russo GT, Giandalia A, et al. Antihypertensive treatment in diabetic kidney disease: The need for a patient-centered approach. Medicina. 2019;55(7):382. Search in Google Scholar

39 El Mouhayyar C, Riachy R, Khalil AB, Eid A, Azar S. Inhibitors in diabetes and microvascular complications: A review. Int J Endocrinol. 2020;2020:1762164. Search in Google Scholar

40 Ozbilgin S, Ozkardesler S, Akan M, Boztas N, Ozbilgin M, Ergur BU, et al. Renal ischemia/reperfusion injury in diabetic rats: The role of local ischemic preconditioning. Biomed Res Int. 2016;2016:8580475. Search in Google Scholar

41 Chowdhury S, Ghosh S, Das AK, Sil PC. Ferulic acid protects hyperglycemia-induced kidney damage by regulating oxidative insult, inflammation and autophagy. Front Pharmacol. 2019;10(FEB). Search in Google Scholar

42 Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351-8. Search in Google Scholar

43 Suzuki K, Ota H, Sasagawa S, Sakatani T, Fujikura T. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem. 1983;132(2):345-52. Search in Google Scholar

44 Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961;93(2):440-7. Search in Google Scholar

45 Daude RB, Shah JS. Protective effect of alpha-cyperone in renal ischemia-reperfusion induced acute kidney injury by modulation of metalloenzyme expression. Eur Chem Bull. 2023;12:5629-43. Search in Google Scholar

46 Pourghasem M, Shafi H, Babazadeh Z, Zahra F. Histological changes of kidney in diabetic nephropathy Caspian. Caspian J Intern Med. 2015;6. Search in Google Scholar

47 de Ponte MC, Cardoso VG, Gonçalves GL, Costa-Pessoa JM, Oliveira-Souza M. Early type 1 diabetes aggravates renal ischemia/reperfusion-induced acute kidney injury. Sci Rep. 2021;11(1). Search in Google Scholar

48 Naylor RW, Morais MRPT, Lennon R. Complexities of the glomerular basement membrane. Nat Rev Nephrol. 2021;17:112-27. Search in Google Scholar

49 Ali MM, Mahmoud AM, Le Master E, Levitan I, Phillips SA. Role of matrix metalloproteinases and histone deacetylase in oxidative stress-induced degradation of the endothelial glycocalyx. Am J Physiol Heart Circ Physiol. 2019;316:647-63. Search in Google Scholar

50 Rosas-Martínez L, Rodríguez-Muñoz R, Namorado-Tonix M del C, Missirlis F, del Valle-Mondragón L, Sánchez-Mendoza A, et al. Hyperglycemic levels in early stage of diabetic nephropathy affect differentially renal expression of claudins-2 and -5 by oxidative stress. Life Sci. 2021;268. Search in Google Scholar

51 Ramnath RD, Butler MJ, Newman G, Desideri S, Russell A, Lay AC, et al. Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease. Kidney Int. 2020;97(5):951-65. Search in Google Scholar

52 Kumar Bhatt L, Addepalli V. Minocycline with aspirin: An approach to attenuate diabetic nephropathy in rats. Ren Fail. 2011;33(1):72-8. Search in Google Scholar

53 Tong Y, Liu S, Gong R, Zhong L, Duan X, Zhu Y. Ethyl vanillin protects against Kidney injury in diabetic nephropathy by inhibiting oxidative stress and apoptosis. Oxid Med Cell Longev. 2019;2019. Search in Google Scholar

54 Zang Y, Igarashi K, Li YL. Anti-diabetic effects of luteolin and luteolin-7-O-glucoside on KK-Ay mice. Biosci Biotechnol Biochem. 2016;80(8):1580-6. Search in Google Scholar

55 Zhang Y, Tian XQ, Song XX, Ge JP, Xu YC. Luteolin protect against diabetic cardiomyopathy in rat model via regulating the AKT/GSK-3β signalling pathway. Biomed Res. 2017;28(3). Search in Google Scholar

56 Shen SC, He F, Cheng C, Xu BL, Sheng JL. Uric acid aggravates myocardial ischemia –reperfusion injury via ROS/NLRP3 pyroptosis pathway. Biomed Pharmacother. 2021;133:110990. Search in Google Scholar

57 Jalal DI, Maahs DM, Hovind P, Nakagawa T. Uric acid as a mediator of diabetic nephropathy. Semin Nephrol. 2011;31(5):459-65. Search in Google Scholar

58 Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: An inception cohort study. Diabetes. 2009;58(7):1668-71. Search in Google Scholar

59 Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 2013;83:1029-41. Search in Google Scholar

60 Kalbolandi SM, Gorji AV, Babaahmadi-Rezaei H, Mansouri E. Luteolin confers renoprotection against ischemia – reperfusion injury via involving Nrf2 pathway and regulating miR320. Mol Biol Rep. 2019;46(4):4039-47. Search in Google Scholar